Urinary cannabinoid disposition in occasional and frequent smokers: Is THC-glucuronide in sequential urine samples a marker of recent use in frequent smokers?

Clinical Chemistry

Volumn 60, Issue 2, 2014, Pages 361-372

  Desrosiers, Nathalie A ^a,b   Lee, Dayong ^a,b   Concheiro Guisan, Marta ^a   Scheidweiler, Karl B ^a   Gorelick, David A ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCURONIDE; TETRAHYDROCANNABINOL DERIVATIVE; BIOLOGICAL MARKER; CANNABINOID;

ADULT; CANNABIS SMOKING; CONFERENCE PAPER; CREATININE URINE LEVEL; DRUG DISPOSITION; DRUG URINE LEVEL; FEMALE; FREQUENT SMOKER; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MIDDLE AGED; NORMAL HUMAN; OCCASIONAL SMOKER; TANDEM MASS SPECTROMETRY; URINALYSIS; YOUNG ADULT; ADOLESCENT; BIOLOGICAL MODEL; CLINICAL TRIAL; LIMIT OF DETECTION; PREDICTIVE VALUE; PROCEDURES; SUBSTANCE ABUSE; TISSUE DISTRIBUTION; URINE;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CANNABINOIDS; FEMALE; GLUCURONIDES; HUMANS; LIMIT OF DETECTION; MALE; MARIJUANA SMOKING; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; SUBSTANCE ABUSE DETECTION; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84893508756     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2013.214106     Document Type: Conference Paper

References (33)

1. United Nations Office on Drugs and Crime (UNODC). World drug report 2013. http://www.unodc.org/unodc/secured/wdr/wdr2013/World-Drug-Report-2013.pdf (Accessed August 2013).
2. Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 1980;215:35-44.
3. Niedbala RS, Kardos KW, Fritch DF, Kardos S, Fries T, Waga J, et al. Detection of marijuana use by oral fluid and urine analysis following singledose administration of smoked and oral marijuana. J Anal Toxicol 2001;25:289-303.
4. Manno JE, Manno BR, Kemp PM, Alford DD, Abukhalaf IK, McWilliams ME, et al. Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9- tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid. J Anal Toxicol 2001;25:538-49.
5. Gustafson RA, Levine B, Stout PR, Klette KL, George MP, Moolchan ET, Huestis MA. Urinary cannabinoid detection times following controlled oral administration of delta9-tetrahydrocannabinol to humans. Clin Chem 2003;49:1114-24.
6. Gustafson RA, Kim I, Stout PR, Klette KL, George MP, Moolchan ET, et al. Urinary pharmacokinetics of 11-nor-9-corboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. J Anal Toxicol 2004;28:160-7.
7. Glaz-Sandberg A, Dietz L, Nguyen H, Oberwittler H, Aderjan R, Mikus G. Pharmacokinetics of 11-nor-9-carboxy-delta (9)-tetrahydrocannabinol (CTHC) after intravenous administration of CTHC in healthy human subjects. Clin Pharmacol Ther 2007;82:63-9.
8. Goodwin RS, Darwin WD, Chiang CN, Shih M, Li S-H, Huestis MA. Urinary elimination of 11-nor-9-carboxy-delta9-tetrahydrocannabinol in cannabis users during continuously monitored abstinence. J Anal Toxicol 2008;32:562-6.
9. Lowe R, Abraham T, Darwin W, Herning R, Cadet J, Huestis M. Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend 2009;105:24-32.
10. Smith ML, Barnes AJ, Huestis MA. Identifying new cannabis use with urine creatininenormalized THCCOOH concentrations and time intervals between specimen collections. J Anal Toxicol 2009;33:185-9.
11. Schwilke EW, Gullberg RG, Darwin WD, Chiang CN, Cadet JL, Gorelick DA, et al. Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users. Addiction 2011;106:499-506.
12. Smith-Kielland A, Skuterud B, Morland J. Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 1999;23:323-32.
13. Kelly P, Jones RT. Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 1992;16:228-35.
14. Karschner E, Schwilke E, Lowe R, Darwin W, Pope H, Herning R, et al. Do Delta9-tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users? Addiction 2009;104:2041-8.
15. Bergamaschi MM, Karschner EL, Goodwin RS, Scheidweiler KB, Hirvonen J, Queiroz RH, Huestis MA. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin Chem 2013;59:519-26.
16. Mareck U, Haenelt N, Geyer H, Guddat S, Kamber M, Brenneisen R, et al. Temporal indication of cannabis use by means of THC glucuronide determination. Drug Test Anal 2009;1:505-10.
17. Mazur A, Lichti CF, Prather PL, Zielinska AK, Bratton SM, Gallus-Zawada A, et al. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 2009;37:1496-504.
18. Felli M, Martello S, Chiarotti M. LC-MS-MS method for simultaneous determination of THCCOOH and THCCOOH-glucuronide in urine: application to workplace confirmation tests. Forensic Sci Int 2011;204:67-73.
19. Skopp G, Pötsch L, Ganßmann B, Mauden M, Richter B, Aderjan R, Mattern R. Freie und glucuronidierte Cannabinoide im Urin: Untersuchungen zur Einschätzung des Konsumverhaltens. Rechtsmedizin 1999;10:21-8.
20. Skopp G, Potsch L An investigation of the stability of free and glucuronidated 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid in authentic urine samples. J Anal Toxicol 2004;28:35-40.
21. Weinmann W, Vigt S, Goerke R, Muller C, Bromberger A. Simultaneous determination of THC-COOH and THC-COOH-glucuronide in urine samples by LC/MS/MS. Forensic Sci Int 2000;113:381-7.
22. Dietz L, Glaz-Sandberg A, Nguyen H, Skopp G, Mikus G, Aderjan R. The urinary disposition of intravenously administered 11-nor-9-carboxydelta-9- tetrahydrocannabinol in humans. Ther Drug Monit 2007;29:368-72
23. Abraham TT, Lowe RH, Pirnay SO, Darwin WD, Huestis MA. Simultaneous GC-EI-MS determination of Delta9-tetrahydrocannabinol, 11-hydroxy-Delta9- tetrahydrocannabinol, and 11-nor-9-carboxy-Delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 2007;31:477-85.
24. Kemp PM, Abukhalaf IK, Manno JE, Manno BR, Alford DD, McWilliams ME, et al. Cannabinoids in humans. II. The influence of three methods of hydrolysis on the concentration of THC and two metabolites in urine. J Anal Toxicol 1995;19:292-8.
25. Scheidweiler KB, Desrosiers NA, Huestis MA. Simultaneous quantification of free and glucuronidated cannabinoids in human urine by liquid chromatography tandem mass spectrometry. Clin Chim Acta 2012;413:1839-47.
26. Department of Health and Human Services (DHHS). Mandatory guidelines for federal workplace drug testing. Federal Register 2008;73:71858-907. http://www.gpo.gov/fdsys/pkg/FR-2008-11-25/pdf/E8-26726.pdf (Accessed August 2013).
27. World Anti-Doping Agency (WADA). Decision limits for the confirmatory quantification of threshold substances. http://www.wada-ama.org/Documents/World- Anti-Doping-Program/WADP-IS-Laboratories/Technical-Documents/ WADA-TD2013DL-Decision-Limits-for-the-Confirmatory-Quantification-Threshold- Substances-2.0-EN.pdf (Accessed August 2013).
28. Bergamaschi MM, Barnes A, Queiroz RH, Hurd YL, Huestis MA. Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Anal Bioanal Chem 2013;405:4679-89.
29. Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci 2007;80:1415-9.
30. Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther 2006;10:29-40.
31. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34:352-63.
32. Schwope DM, Karschner EL, Gorelick DA, Huestis MA. Identification of recent cannabis use: wholeblood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration. Clin Chem 2011;57:1406-14.
33. Ramaekers JG, Moeller MR, Van Ruitenbeek P, Theunissen EL, Schneider E, Kauert G. Cognition and motor control as a function of Delta9-THC concentration in serum and oral fluid: limits of impairment. Drug Alcohol Depend 2006;85:114-22.